DUPILUMAB IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC OESOPHAGITIS – DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 1–11 YEARS, WITH ACTIVE EOSINOPHILIC OESOPHAGITIS

Mirna Chehade  ¹     Evan S. Dellon  ²     Marc E. Rothenberg  ³     Bin Yao  ⁴     Elizabeth Laws  ⁵     Nikhil Amin  ⁴     Marcella Ruddy  ⁴     Bethany Beazley  ⁴     Kiran Patel  ⁵     Veronica Mas Casullo  ⁴     Jonathan Spergel  ⁶     Leda Mannent  ^7    
1 Icahn School of Medicine at Mount Sinai, New York, United States
² University of North Carolina School of Medicine, Chapel Hill, United States
³ Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, United States
⁴ Regeneron Pharmaceuticals, Inc., Tarrytown, United States
⁵ Sanofi, Bridgewater, United States
⁶ Children's Hospital of Philadelphia, Philadelphia, United States
⁷ Sanofi, Chilly-Mazarin, France

Session
Oesophageal, gastric and duodenal disorders (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)